Clinical Trials List
2024-05-01 - 2031-08-31
Phase I/II
Recruiting4
ICD-10C15.5
Malignant neoplasm of lower third of esophagus
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9150.2
Malignant neoplasm of abdominal esophagus
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 呂理駿 Division of Hematology & Oncology
- 郭弘揚 Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
- Kun-Huei Yeh Division of Hematology & Oncology
- 梁逸歆 Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hung-Yuan Yu Digestive System Department
- 翁敬堯 Division of Radiology
- Muh-Hwa Yang Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- Tien-Hua Chen Division of Hematology & Oncology
- Chueh-Chuan Yen Division of Hematology & Oncology
- 唐振育 Division of Hematology & Oncology
- 陳宥任 Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- Yun-Cheng Hsieh Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王幸婷 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- 王秀慈 Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Chang-Fang Chiu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
36 participants
-
Global
130 participants
